Curing the Few, Billing the Many

Rare disease therapies are on track to top $400B in global sales by 2032, buoyed by policy tailwinds and a blockbuster pipeline

2 Apr 2026

There is something striking about a market segment defined by scarcity becoming one of pharma's most valuable properties. Therapies for rare diseases, once considered a niche pursuit, are on course to generate more than $400 billion in annual global revenues by 2032, according to Evaluate's 2026 Orphan Drug Report. That figure would represent over 21% of all prescription drug sales, roughly equivalent to the entire prescription market of two decades ago.

The gains are not evenly spread. Eight orphan franchises are each forecast to exceed $6 billion in annual sales by 2032. Johnson & Johnson's Darzalex leads the pack, with projected revenues approaching $31 billion. A subcutaneous formulation has extended its commercial shelf life by making administration easier for patients. The late-stage pipeline across the sector is collectively projected to add more than $100 billion more.

Policy has helped. Amendments to the Inflation Reduction Act now shield multi-indication orphan drugs from Medicare price negotiations, removing a disincentive that had discouraged developers from pursuing additional disease labels. The Rare Pediatric Disease Priority Review Voucher programme, which had lapsed for over a year, was restored through September 2029 under a spending act signed in February 2026. Such vouchers have historically traded at between $75 million and $150 million each, making them a meaningful financial lever.

Yet the story is not without complications. Major pharmaceutical companies face an estimated $300 billion revenue gap from approaching patent expiries, and capital is increasingly flowing toward obesity blockbusters as a result. Orphan drugs' share of the overall prescription market is forecast to slip modestly over the coming seven years, even as their absolute revenues keep climbing.

The rare disease sector, then, finds itself in an unusual position: growing fast in nominal terms, losing ground in relative ones. Whether the pipeline and policy advantages are enough to sustain the momentum, or whether the pull of larger markets dilutes the industry's commitment to rare conditions, remains the central tension facing investors and developers alike.